Shots:

• SURPASS-4 study involves assessing tirzepatide (5/10/15mg) vs insulin glargine in 2002 adults in a ratio (1:1:1:3) with T2D inadequately controlled with at least 1 and up to 3 oral antihyperglycemic medications who have increased CV risk
• The study met its 1EPs and 2EPs led to superior A1C and body weight reductions for both estimands. @52wks. A1C reduction (-2.24% / -2.43%/ -2.58% vs -1.44%); Weight reduction (-7.1/ -9.5/ -11.7kg vs +1.9 kg); patients achieving A1C <7% (81.0%/ 88.2%/ 90.7% vs 50.7%); patients achieving A1C <5.7% (23.0%/ 32.7%/ 43.1% vs 3.4%) respectively
• Lilly plan to submit registration package to regulatory authorities by the end of 2021

  Ref: PRNewswire | Image: Fox Business